The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID
MWN-AI** Summary
On November 12, 2025, The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences announced a significant advancement in the development of a second-generation fungal vaccine, VXV-01. This initiative is bolstered by a remarkable contract valued at up to $40 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The funding will enable the progress of VXV-01 through manufacturing and non-clinical studies, culminating in two Phase 1 clinical trials aimed at assessing safety and immunogenicity.
VXV-01, designed using TLI’s innovative Therapeutic & Laboratory Immunology technology platform, targets invasive Candida infections and aims to provide broader-spectrum protection against Gram-negative infections that are commonly associated with healthcare settings. The strategic partnership between Vitalex and Appili Therapeutics, a biopharmaceutical firm focused on combating serious infections, highlights the collaborative effort to leverage this funding effectively for the comprehensive development of VXV-01.
Principal Investigator Dr. Ashraf Ibrahim expressed optimism about this development, noting the contract as a pivotal moment that enhances the potential for VXV-01 to transition from concept to human application. This second-generation vaccine is engineered for robust immunogenicity and scalability, addressing a critical unmet need in infectious disease prevention.
Additionally, Vitalex has received over $10 million in non-dilutive funding to further develop technologies addressing multidrug-resistant infections. The progression of VXV-01 into clinical trials marks a crucial step towards delivering an effective solution for serious fungal infections, aiming to improve patient outcomes and address significant public health concerns globally.
MWN-AI** Analysis
The recent announcement regarding The Lundquist Institute (TLI) and its startup, Vitalex Biosciences, signals significant advancements in the biotech sector, particularly in combating fungal infections. With the awarding of a $40 million contract from the NIH/NIAID for the development of the second-generation vaccine candidate, VXV-01, investors should consider several factors that could shape the market outlook for both Vitalex and TLI.
Firstly, the financial backing of $40 million is a strong endorsement of the vaccine’s potential and reflects a commitment to addressing a critical and growing public health concern—hospital-acquired fungal infections. This non-dilutive funding means that Vitalex can pursue significant advancements without equity dilution, preserving company valuation for existing shareholders.
Secondly, VXV-01's unique dual-antigen approach designed for broader protection against both Candida infections and Gram-negative bacteria positions it strongly in a market with pressing unmet needs. The vaccine's potential to improve patient outcomes could make it attractive for partnerships with larger pharmaceutical firms, enhancing its growth trajectory.
Moreover, the transition to Phase 1 trials marks a pivotal scientific milestone that can stimulate investor interest and increase the company's market valuation. If successful, this can set the stage for further funding rounds, partnerships, or potential acquisitions as larger pharmaceutical companies seek innovative therapies.
From an investment standpoint, it would be prudent to keep an eye on upcoming trial results and regulatory updates for VXV-01. The biotech sector can be volatile, and while the current developments are promising, they also introduce risk due to the uncertainties surrounding clinical outcomes and regulatory approval processes. Therefore, maintaining a balanced portfolio and considering exposure in relation to risk tolerance is advisable. Overall, Vitalex and TLI present a compelling case for investment as the development of VXV-01 progresses, given its potential impact on public health and the significant financial backing it has received.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Los Angeles, California, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV?01, which was developed using a proprietary TLI vaccine technology platform, is poised to move forward in development up to and including Phase 1 clinical evaluation — enabled by a major contract awarded to a collaboration consortium of Vitalex and Appili Therapeutics (TSX: APLI; OTCPink: APLIF). The contract from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) is valued at up to US $40 million. It will support the development of VXV-01 from manufacturing and non-clinical studies through two Phase 1 clinical trials. This contract represents a significant milestone for The Lundquist Institute’s vaccine research program.
Key Highlights
- Vitalex has an exclusive option to license VXV-01 from TLI for commercial development.
- The contract, awarded by NIH/NIAID, provides up to US $40 million of non-dilutive funding to Vitalex and its collaborator Appili and for the comprehensive development of VXV-01.
- VXV-01 is built on the TLI (Therapeutic & Laboratory Immunology) technology platform developed at TLI, a second-generation approach containing two antigens designed to target invasive Candida infections with broader-spectrum cross-kingdom protection potential against Gram-negative healthcare-associated infections.
- With this funding, the program is positioned to begin manufacturing and other preparations necessary to initiate two Phase 1 clinical trials , which, when they occur, will mark a transition from preclinical research into the first stage of human testing.
- Advancing VXV-01 into development up to and including Phase 1 trials brings it one step closer to delivering a novel prophylactic solution for serious fungal infections, a major unmet need in infectious disease.
“Securing this contract is a pivotal moment for our team,” said Ashraf Ibrahim, PhD, Principal Investigator and VXV-01 program lead at TLI and CEO of Vitalex. “By putting VXV-01 into development through human trials, we are significantly increasing our chances of making this vaccine a reality. It is the culmination of years of work on our TLI technology platform and reflects our commitment to tackling high-impact infectious disease challenges.”
About VXV-01
VXV-01 is a dual-antigen fungal vaccine candidate designed to elicit robust immunity against key opportunistic and hospital-associated Candida and Gram-negative bacterial pathogens. Built at TLI and further developed by Vitalex, VXV-01 is engineered for strong immunogenicity, manufacturability and scalability. The move into Phase 1 human trials marks the transition from lab and animal model proof-of-concept to human safety and immunogenicity studies.
About The Lundquist Institute
Founded in 1952, The Lundquist Institute (TLI) is a leading nonprofit research organization at the heart of Los Angeles County’s life sciences ecosystem. Guided by a “bedside to bench to bedside” approach, TLI bridges cutting-edge discovery and real-world health impact. Through strong community partnerships, TLI conducts research that addresses pressing health needs, advances technology transfer and commercialization, and accelerates the path from breakthrough science to practical solutions that improve lives locally and globally. For more information, visit lundquist.org.
About Vitalex
Vitalex is a start-up company created to further the development of technologies discovered in the laboratory of its founder, Dr Ashraf S. Ibrahim, a senior investigator at TLI and a Professor at the David Geffen School of Medicine at UCLA. Vitalex has obtained >$10 million in non-dilutive funding from the NIAID to further the development of a dual antigen vaccine that targets hospital-acquired infections caused by multidrug-resistant Candida albicans, Candida auris, and Gram-negative bacteria, including those caused by Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Vitalex is also developing a humanized monoclonal antibody against mucormycosis, a lethal and rare fungal infection. For more information, visit www.vitalexbiosciences.com .
About Appili Therapeutics
Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the center of the global fight against infection. For more information, visit www.AppiliTherapeutics.com .
Forward-Looking Statements
This press release contains forward-looking statements regarding the development of VXV-01, including its advancement into clinical trials, the benefits of the TLI technology platform, and the potential for VXV-01 to become a realized vaccine. Actual results may differ materially from those projected due to risks and uncertainties, including regulatory approval, clinical trial outcomes, manufacturing challenges, and funding uncertainties.
Jennifer StrongThe Lundquist Institute for Biomedical Innovation310-974-9300jennifer.strong@lundquist.org
FAQ**
How does the partnership between Vitalex Biosciences and Appili Therapeutics Inc. (APLI:CC) enhance the development and commercialization prospects of the VXV-01 vaccine candidate?
What specific roles and contributions will Appili Therapeutics Inc. (APLI:CC) provide in the Phase 1 clinical trials for the VXV-01 vaccine?
Given the involvement of Appili Therapeutics Inc. (APLI:CC), what synergies can be expected in addressing the urgent need for novel therapies against multidrug-resistant infections?
How does the financing from the NIH/NIAID to Vitalex Biosciences and Appili Therapeutics Inc. (APLI:CC) support the strategic goals of both companies while reducing financial risks in the vaccine development process?
**MWN-AI FAQ is based on asking OpenAI questions about Appili Therapeutics Inc. (TSXC: APLI:CC).
NASDAQ: APLI:CC
APLI:CC Trading
0.0% G/L:
$0.07 Last:
87,908 Volume:
$0.07 Open:
